1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
IBCL - 907
Retrospective Analysis of Cardiovascular Risk Assessment Prior to BTK Inhibitor Treatment for Patients with CLL and B-cell Lymphomas
Poster Presenter
Authors
Part of Topic
Indolent B-Cell Lymphoma (IBCL)
Title: Retrospective Analysis of Cardiovascular Risk Assessment Prior to BTK Inhibitor Treatment for Patients with CLL and B-cell Lymphomas
Introduction:
•BTK inhibitors (BTKi) are a cornerstone therapy for CLL and other B-cell malignancies.
•Cardiovascular (CV) toxicity remains a key safety consideration that can limit BTKi use and affect patient outcomes.
•Expert consensus guidelines recommend baseline CV assessment prior to BTKi initiation, but real-world practices vary widely.
Aims:
•Retrospectively analyze the CV risk assessment performed prior to BTKi initiation.
•Identify clinician-reported knowledge and barriers to CV assessment prior to BTKi initiation as part of an institutional quality improvement initiative.
Methods:
•Design: IRB-approved, single-center retrospective cohort study.
•Population: Adults with CLL/SLL or B-cell lymphoma initiated on BTKi therapy between 2021–2026 at Loyola identified through pharmacy database.
Measures:
•Baseline ECG: Assessed for completion within 30 days prior to BTKi initiation.
•TTE indication: Defined as pre-existing cardiovascular disease, ≥2 cardiovascular risk factors, or an abnormal ECG.
•Complete CV assessment: Defined as an ECG within 30 days and, when indicated, a TTE within 6 months prior to BTKi initiation.
•Survey to physicians and APPs to identify knowledge and barriers to CV assessment.
Conclusions:
•Limitations: Single center; pharmacy database incomplete and more patients to be analyzed; different treating physicians during the study timeline and at the time of the survey.
•Despite consensus recommendations supporting baseline ECG and risk-based CV assessment prior to BTKi treatment, the real-world implementation is low and remains inadequate overall.
•This data is the basis of a quality improvement initiative aimed at standardizing the cardiovascular evaluation prior to BTKi initiation in patients with CLL and other B-cell lymphomas.